A class action lawsuit has been filed against Intellia Therapeutics, Inc., alleging violations of federal securities laws. The complaint centers on statements made by the company concerning its Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease.
The lawsuit alleges that Intellia provided investors with material information, including confidence in the timeline for the NTLA-3001 study and expectations to dose the first patient in the second half of 2024. However, the complaint claims the company failed to disclose that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became more cost-effective and efficient.
The truth, according to the complaint, emerged on January 9, 2025, when Intellia announced a strategic reorganization. This reorganization included halting all NTLA-3001 research and studies and reducing its workforce by 27% in 2025, leading to the discontinuation of the once-touted program. The class period for the lawsuit is from July 30, 2024, to January 8, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.